{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:22:51Z","timestamp":1787696571540,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mcna.2020.09.009","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T06:02:33Z","timestamp":1613368953000},"page":"227-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rheumatic Complications of Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"105","author":[{"given":"Nilasha","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6382","key":"10.1016\/j.mcna.2020.09.009_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.009_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.mcna.2020.09.009_bib4","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.009_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2020.09.009_bib6","doi-asserted-by":"crossref","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.009_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A\u00a0systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"34","key":"10.1016\/j.mcna.2020.09.009_bib10","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.009_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.009_bib12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.009_bib14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.009_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.mcna.2020.09.009_bib16","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mcna.2020.09.009_bib17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.009_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.009_bib19","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/rheumatology\/kew279","article-title":"Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria","volume":"55","author":"Leung","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor\u2013induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"18","key":"10.1016\/j.mcna.2020.09.009_bib25","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.009_bib26","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7756","key":"10.1016\/j.mcna.2020.09.009_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2020.09.009_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series","author":"Ghosh","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.009_bib32","doi-asserted-by":"crossref","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune checkpoint inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.009_bib34","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A\u00a0new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.009_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.009_bib37","doi-asserted-by":"crossref","first-page":"e0192704","DOI":"10.1371\/journal.pone.0192704","article-title":"Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression","volume":"13","author":"Guo","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.009_bib38","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.009_bib39","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib40","doi-asserted-by":"crossref","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.mcna.2020.09.009_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/00124743-900000000-99055","article-title":"Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica\/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab","author":"Betrains","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.009_bib42","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.009_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/BOR.0000000000000353","article-title":"Role of low-grade inflammation in osteoarthritis","volume":"29","author":"Scanzello","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.mcna.2020.09.009_bib44","unstructured":"<pi_opdivo.pdf>. In: Squibb B-M, editor. packageinserts. Available at: packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed October 23, 2020."},{"key":"10.1016\/j.mcna.2020.09.009_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.009_bib46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2020.09.009_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10124","key":"10.1016\/j.mcna.2020.09.009_bib48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.009_bib49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.009_bib50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1078155217701292","article-title":"Could knee inflammatory synovitis be induced by pembrolizumab?","volume":"24","author":"Mahmoud","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"21","key":"10.1016\/j.mcna.2020.09.009_bib51","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.mcna.2020.09.009_bib52","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.009_bib53","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.009_bib54","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.009_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.009_bib56","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune checkpoint inhibitor-induced sarcoidosis-like granulomas","volume":"24","author":"Rambhia","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.009_bib57","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.009_bib58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:45:54Z","timestamp":1671277554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712520301218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0025712520301218"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.009","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatic Complications of Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}